A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer

Inclusion Criteria

• •Age ≥ 18 years
• •ECOG performance score of 0-2
• •Signed informed consent
• •Histologically confirmed AR+ breast cancer
• •* All participants under consideration for enrollment will have their tumor specimen tested centrally at MSK; nuclear AR staining ≥ 1% will be considered positive.
• •Progressive metastatic breast cancer manifested as increase in evaluable disease OR the appearance of new sites of disease since the date of the last imaging study performed and under consideration for AR-targeted therapy
• •Planning to undergo treatment with agents targeting the antiandrogen signaling pathway on a clinical trial